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The in vivo efficacy of posaconazole against 4 clinical Aspergillus fumigatus isolates with posaconazole MICs
ranging from 0.03 to 16 mg/liter, as determined by CLSI method M38A, was assessed in a nonneutropenic
murine model of disseminated aspergillosis. The underlying resistance mechanisms of the isolates included
substitutions in the cyp51A gene at codon 220 (M220I), codon 54 (G54W), and codon 98 (L98H). The latter was
combined with a 34-bp tandem repeat in the gene promoter region (TR L98H). The control isolate exhibited
a wild-type phenotype without any known resistance mechanism. Oral posaconazole therapy was started 24 h
after infection and was given once daily for 14 consecutive days. Mice were treated with four different doses (1
to 64 mg/kg of body weight), and survival was used as the end point. Survival was dependent both on the dose
and on the MIC. The Hill equation with a variable slope fitted the relationship between the dose/MIC ratio and
14-day survival well (R2, 0.92), with a 50% effective dose (ED50) of 29.0 mg/kg (95% confidence interval [CI],
15.6 to 53.6 mg/kg). This also applied to the relationship between the area under the plasma concentration-time
curve (AUC)/MIC ratio and 14-day survival (50% effective pharmacodynamic index [EI50], 321.3 [95% CI,
222.7 to 463.4]). Near-maximum survival was reached at an AUC/MIC ratio of nearly 1,000. These results
indicate that treatment of infections with A. fumigatus strains for which MICs are 0.5 mg/liter requires doses
exceeding the present licensed doses. Increasing the standard dosing regimen may have some effect and may
be clinically useful if no alternatives are available.
Over recent years, Aspergillus fumigatus has become the
most widespread opportunistic fungal pathogen, causing se-
vere and commonly fatal invasive fungal infections in immu-
nocompromised hosts (2, 4, 15). Management of invasive as-
pergillosis includes prompt treatment with an appropriate
antifungal agent at an adequate dose, but patients may fail to
respond for many reasons, including the persistence of the
underlying condition and associated neutropenia. Although
Aspergillus resistance to antifungal compounds is considered
uncommon, treatment failure due to acquired resistance of A.
fumigatus has been reported more frequently in recent years
than it was formerly (8, 16, 22, 31). Azole resistance has been
observed in patients with aspergilloma and cavitary aspergillo-
sis who developed resistance during treatment with azoles,
most notably itraconazole (6, 8–10, 13, 22). However, azole
resistance has also been reported for patients with invasive
aspergillosis (25, 28, 29). In addition to pulmonary infections,
cases of disease due to azole-resistant isolates have been re-
ported for a patient with osteomyelitis and patients with cen-
tral nervous system aspergillosis (12, 27).
Azole antifungals impair the ergosterol biosynthesis pathway
via the inhibition of the lanosterol 14-demethylase, which is a
product of the cyp51 gene in A. fumigatus. This enzyme re-
moves the methyl group at position C-14 of precursor sterols.
In A. fumigatus, there are two distinct but related cyp51 pro-
teins, encoded by cyp51A and cyp51B (18), respectively. Dif-
ferent modifications in the cyp51 gene appear to be associated
with the mechanism of azole resistance. These cyp51 modifica-
tions were found to be due to specific mutations in the cyp51A
gene, and each mutation is associated with a distinct pheno-
type. The associated phenotype is commonly characterized by
a lack of itraconazole activity, but also by reduced activities of
the other azole compounds. A phenotype with no itraconazole
or posaconazole activity in vitro has been associated with
amino acid substitutions at glycine 54 (G54) (17, 22). A phe-
notype with no itraconazole activity but elevated voriconazole
and posaconazole MICs was linked to different amino acid
substitutions at methionine 220 (M220) (6, 19). Another A.
fumigatus resistance mechanism involved a base change caus-
ing an amino acid substitution in cyp51A at codon 98 in com-
bination with the duplication in tandem of a 34-bp sequence in
the cyp51A promoter (TR L98H) (20, 25). The corresponding
phenotype was characterized by a lack of itraconazole activity
and reduced voriconazole and posaconazole activities.
Given the prominent and increasing role of azoles in the
management of Aspergillus diseases, it is important to deter-
mine if increased MICs correspond with reduced in vivo effi-
cacy. We investigated the correlation between the in vitro and
in vivo activities of posaconazole in a nonneutropenic murine
model of disseminated invasive aspergillosis in order to deter-
mine the pharmacokinetic (PK)-pharmacodynamic properties
of posaconazole. For this purpose we used three clinical iso-
lates with different profiles of susceptibility to azoles, which
appear to be related to distinct cyp51A substitutions.
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Isolates. Four clinical A. fumigatus isolates were used in this study. Clinical
isolates with non-wild-type susceptibility included those with the following sub-
stitutions in Cyp51A: M220I (isolate identification number, V28-77), G54W
(V59-73), and TR L98H (V52-35). A clinical isolate without substitutions in
cyp51A was used as a control (AZN8196). For all isolates, the cyp51A substitu-
tions and strain identifications were confirmed by sequence-based analysis as
described previously (25) (Table 1). In addition, microsatellite typing of the four
isolates by short tandem-repeat typing (16) was performed to confirm that they
were genetically distinct. The isolates had been stored in 10% glycerol broth at
80°C and were revived by subculturing on Sabouraud dextrose agar (SAD)
supplemented with 0.02% chloramphenicol for 5 to 7 days at 35°C.
Susceptibility testing was performed based on method M38A of the Clinical
and Laboratory Standards Institute (CLSI) using a broth microdilution format
(23).
Infection model. A total of 264 outbred CD-1 (Harlan, Horst, The Nether-
lands) female mice, 4 to 5 weeks old, weighing 20 to 25 g, were randomized into
6 groups (11 mice per group) for the four different A. fumigatus strains. Before
the experiment, the isolate was cultured once on SAD for 7 days at 35°C and
subcultured twice on 15-cm Takashio slants for 5 days at 35°C. The conidia were
harvested in 20 ml of sterile phosphate-buffered saline (PBS) plus 0.1% Tween
80 (Boom B.V., Meppel, The Netherlands). The conidial suspension was filtered
through sterile gauze folded four times to remove any hyphae, and the number
of conidia was counted in a hemacytometer. After the inoculum was adjusted to
the required concentration, the conidial suspension was stored overnight at 4°C.
The 90% lethal dose (LD90) was determined for each isolate.
Mice were infected via injection of an inoculum corresponding to the LD90 of
the isolate into the lateral tail vein. The LD90s were 2.4 107 (wild-type control),
2.5  107 (TR L98H mutant), 5  107 (M220I mutant), and 1  107 (G54W
mutant) conidia, respectively. Postinfection viability counts of the injected inoc-
ula were determined to ensure that the correct inoculum had been injected.
Therapy was begun 24 h after infection and continued for 14 days. A posacon-
azole (Schering-Plough B.V., Boxmeer, The Netherlands) oral solution was ad-
ministered in doses of 1, 4, 16, and 64 mg/kg of body weight by oral gavage once
daily. Although a dose of 128 mg/kg was used for some groups, it resulted in
toxicity and therefore was not studied further. The control group received single
doses of saline. On day 15 postinfection, all remaining mice were humanely
euthanized under isoflurane anesthesia, and blood was collected through the
orbital vein.
The animals were housed under standard conditions, with drink and feed
supplied ad libitum. The animal studies were conducted in accordance with the
recommendations of the European Community (Directive 86/609/EEC, 24 No-
vember 1986), and all animal procedures were approved by the Animal Welfare
Committee of Radboud University (RU-DEC 2007-30 and RU-DEC 2008-105).
The infected mice were examined at least three times daily. These clinical
inspections were carried out in order to ensure that there were no cases of
desiccation, torticollis, staggering, high weight loss (a decrease of 15% within
48 h or 20% within 24 h), or body temperature drop to below 33°C. Mice
demonstrating these signs of disease were humanely terminated.
Pharmacokinetic analysis. A total of 96 outbred CD-1 (Charles River, The
Netherlands) female mice, 4 to 5 weeks old, weighing 20 to 22 g, were used for
separate PK experiments. On day zero, mice were infected with the wild-type A.
fumigatus isolate through the lateral tail vein, and after 24 h, treatment was
initiated, as described above, with dosages of 1, 4, 16, or 64 mg/kg. At day 2 of
posaconazole treatment (day 3 after infection), blood samples were drawn
through the orbital vein into lithium-heparin-containing tubes at 8 predefined
time points: immediately before administration of posaconazole and subse-
quently at 0.5, 1, 2, 4, 8, 12, and 24 h postdose. Blood samples were centrifuged
for approximately 10 min at 1,000  g within 30 min of collection. Plasma was
aspirated, transferred in two 5-ml plastic tubes, and stored at 70°C. Posacon-
azole samples were measured by a validated (for human and mouse matrices)
high-performance liquid chromatography (HPLC) method with fluorescence
detection. Samples were pretreated using a protein precipitation procedure. The
dynamic range of the assay was 0.05 to 10 mg/liter. The assay had an accuracy
range (n  15 replicates), dependent on the concentration, from 97.9% to
104.1%. Intraday precision ranged from 1.56% to 3.03%, and interday precision
was between 1.37 and 4.11%. The assay was externally validated by an interna-
tional proficiency testing program (5).
Arithmetic mean concentrations of posaconazole in plasma from three mice
were calculated per time point. Peak concentrations in plasma (Cmax) were
directly observed from the data. Pharmacokinetic parameters were derived using
noncompartmental analysis with WinNonLin, version 5.2 (Pharsight, Inc). The
area under the plasma concentration-time curve (AUC) from time zero to 24 h
postinfusion (AUC0–24) was determined by use of the log-linear trapezoidal rule.
The elimination rate constant was determined by linear regression of the termi-
nal points of the log-linear plasma concentration-time curve. The terminal half-
life was defined as ln2 divided by the elimination rate constant. Clearance (CL)
was calculated as dose/AUC0–24.
Statistical analysis. All data analysis was performed by using the software
package of GraphPad Prism, version 5.0, for Windows (GraphPad Software, San
Diego, CA). A regression analysis was conducted to determine linearity between
dose and AUC. Mortality data were analyzed by the log rank test. The survival
data were plotted against dose/MIC and the Hill equation with a variable slope
fitted to the data, both for each individual strain and for pooled survival data.
The goodness of fit was checked by determination of the R2 and visual inspection.
Statistical significance was defined as a P value of 0.05 (two-tailed). Dose/MIC
and AUC/MIC ratios were calculated by dividing the dose (in milligrams per
kilogram of body weight) or the AUC by the MIC. Dose/MIC and AUC/MIC
ratio data were log10 transformed to approximate a normal distribution prior to
statistical analysis.
RESULTS
In vitro activity. The in vitro susceptibility profiles of the four
isolates are presented in Table 1. Posaconazole was the most
active azole in vitro against the wild-type isolate (MIC, 0.031
mg/liter), but its activity against the M220I and TR L98H
mutants (MICs, 0.5 mg/liter) was reduced, and the drug exhib-
ited no significant in vitro activity against the G54W mutant
(MIC, 16 mg/liter). All three cyp51A-mutated isolates
showed no susceptibility to ITZ, with MICs of 16 mg/liter.
Pharmacokinetic analysis. Table 2 shows the results of the
pharmacokinetic experiments. A total of 96 mice (3 mice per
time point, 8 time points, 4 different dosages) were available
for pharmacokinetic assessment. All 96 mice were alive at the
time of the sample collection. The AUC normalized to a dose
of 1 mg/kg resulted in ratios of 10.19, 11.27, 9.96, and 4.64 for
dosages of 1, 4, 16, and 64 mg/kg, respectively. The AUC
correlated significantly with the dose in a linear fashion from 1
TABLE 1. Origins, in vitro susceptibilities, and underlying azole resistance mechanisms of the A. fumigatus isolates
Isolate no. Origin Prior azoleexposure
Cyp51A
substitution
MIC or MEC (mg/liter)a
AMB ITZ VCZ POS CAS
AZN 8196 Proven invasive aspergillosis None 0.5 0.125 0.25 0.031 0.25
V28-77 Aspergilloma ITZ M220I 0.5 16 0.25 0.5 0.25
V52-35 Proven invasive aspergillosisb None TR L98H 0.5 16 2 0.5 0.25
V59-73 Clinical, disease entity unknown Unknown G54W 0.5 16 0.125 16 0.25
a AMB, amphotericin B; ITZ, itraconazole; VCZ, voriconazole; POS, posaconazole; CAS, caspofungin. For caspofungin, the minimum effective concentration
(MEC) was determined; for all other drugs, the MIC was determined.
b See reference 29.
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to 16 mg/kg (R2  0.99). The dosage of 64 mg/kg resulted in a
relatively lower AUC.
Survival curves. The survival curves for all 4 control groups
receiving saline by oral gavage showed a mortality of 90 or
100% and a median survival time of 3 to 3.5 days. Figure 1
shows the survival curves for the 4 isolates by dose. The results
show that for each dose, the response decreased as the MIC
increased. Similarly, when the dose was increased, an improved
response was observed. Table 3 shows a comparison between
the various survival curves within each group/strain. This clearly
shows that statistically significant differences in survival be-
tween treatment and control groups became apparent either
when the dose increased or when the MIC was lower. This
applied to both the median survival time and the survival rate.
The most significant difference was observed between the wild-
type and G54W isolates. While the drug was not effective in the
infection model at any dose for the G54W mutant, a dose as
low as 1 mg/kg had some effect against mice infected with the
wild-type isolate, and all higher posaconazole doses had a near-
maximum effect for this isolate. The treatment effects on TR
L98H and M220I mutant-infected mice were similar, although
the response of mice infected with the isolate containing the
TR L98H mutation to a 4-mg/kg dose was somewhat higher
than that of those infected with the M220I isolate (36.4%
versus 0%, respectively).
Dose-response analysis. The dose-response curves for each
of the four posaconazole dosing regimens and controls for all
four strains are shown in Fig. 2. Posaconazole treatment im-
proved the survival of the mice in a dose-dependent manner
for all four isolates. Compared to that for the wild-type control,
the dose-response curves of mice infected with the M220I or
TR L98H mutant were shifted to the right, indicating that
TABLE 2. Pharmacokinetic parameters of posaconazole after doses of 1 to 64 mg/kg administered by oral gavage
Posaconazole
dose (mg/kg)






liters/(h  kg) C24 (mg/liter) Cavg (mg/liter) Cmax (mg/liter) Tmax (h)
1 10.20 10.19 0.10 0.11 (0.05) 0.42 0.98 (0.21) 4.00
4 45.07 11.27 0.09 0.94 (0.39) 1.88 3.11 (0.68) 2.00
16 159.42 9.96 0.10 2.70 (0.57) 6.64 9.03 (1.75) 8.00
64 296.72 4.64 0.22 9.33 (2.77) 12.36 17.83 (4.60) 8.00
a For Cmax and the concentration at 24 h (C24), values in parentheses are standard deviations (n  3).
FIG. 1. Survival curves of four different isolates of A. fumigatus by posaconazole dose. Shown are data for the wild type (WT) (MIC, 0.031
mg/liter) and for the TR L98H (MIC, 0.5 mg/liter), M220I (MIC, 0.5 mg/liter), and G54W (MIC, 16 mg/liter) mutants.
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higher doses of posaconazole were required to achieve efficacy
similar to those for the wild-type-infected mice, while a maxi-
mal response against the G54W strain could not be reached
even in mice treated with the highest posaconazole dose. A
dose/MIC–survival plot for all four strains is depicted in Fig. 3.
The data indicated a clear sigmoidal dose-response relation-
ship. The Hill-type model fitted the data well, with an R2 of
0.92. The 50% effective dose (ED50) was 29.0 mg/kg (95%
confidence interval [CI], 15.6 to 53.6 mg/kg). This indicates a
direct relationship between MIC, dose, and effect. In total,
82% of the mice were cured when the dose/MIC ratio was
130.
Exposure-response analysis. The AUC for each dose, as
determined from the pharmacokinetic experiments, was used
to calculate the AUC from 0 to 24 h (AUC0–24)/MIC ratios for
each strain. These are shown in Fig. 4. Like the dose-response
relationship, the exposure-response relationship had a sigmoidal
shape. The Hill model with a variable slope fitted the data well,
with an R2 of 0.88. The 50% effective pharmacodynamic index
(EI50) was 321.3 (95% CI, 222.7 to 463.4). Near-maximum
survival was reached at a AUC/MIC ratio of nearly 1,000. We
also determined the Cmax/MIC-response relationship. Because
we used a once-daily dose only, this relationship was compa-
rable to the AUC/MIC relationship. However, the R2 of the
model fit was slightly less, 0.84, because of pharmacokinetic
differences between doses.
DISCUSSION
We investigated the comparative efficacies of various regi-
mens of posaconazole against clinical A. fumigatus cyp51A-
mutated isolates in a nonneutropenic murine model of dissem-
inated aspergillosis. We believe that this research question is
highly relevant, because the azoles are the main drug class for
the management of invasive aspergillosis and the only class
that can be administered orally. Our study shows that the MIC
of the isolate has a major impact on the efficacy of posacon-
azole, an agent shown to be highly active in vitro and in animal
models of invasive aspergillosis due to wild-type A. fumigatus
isolates. We observed a 50% loss of efficacy in those isolates
harboring cyp51A substitutions, i.e., the TR L98H and M220I
substitutions, associated with a phenotype that increased the
MIC of posaconazole by four 2-fold dilution steps, from 0.03 to
0.5 mg/liter. While this loss of efficacy was completely or partly
compensated for by increasing the posaconazole dose, the
TABLE 3. Bonferroni multiple-comparison test for survival curves
Posaconazole
dose (mg/kg)
P value for the difference between treatment and control






64 0.0001* 0.0001* 0.0001* 0.0001*
16 0.0001* 0.0001* 0.0209 0.0018*
4 0.0001* 0.0108 0.1554 0.0724
1 0.0068* 0.0831 0.1554 0.0238
a The Bonferroni Kp value for 4 multiple comparisons was 0.01. P values of
0.01, which indicate a significant difference in survival rates between treatment
and control groups, are asterisked. WT, wild type.
FIG. 2. Fourteen-day survival as a function of posaconazole dose
for 4 A. fumigatus isolates. Shown are data for the wild type (WT)
(MIC, 0.031 mg/liter) and for the TR L98H (MIC, 0.5 mg/liter), M220I
(MIC, 0.5 mg/liter), and G54W (MIC, 16 mg/liter) mutants. The
curves indicate fits with the Hill equation for each isolate.
FIG. 3. Fourteen-day survival as a function of the posaconazole dose/
MIC ratio for 4 A. fumigatus isolates. Shown are data for the wild type
(WT) (MIC, 0.031 mg/liter) and for the TR L98H (MIC, 0.5 mg/liter),
M220I (MIC, 0.5 mg/liter), and G54W (MIC,16 mg/liter) mutants. The
curve is the model fit with the Hill equation for pooled data.
FIG. 4. Fourteen-day survival as a function of the posaconazole AUC/
MIC ratio for 4 A. fumigatus isolates. Shown are data for the wild type
(WT) (MIC, 0.031 mg/liter) and for the TR L98H (MIC, 0.5 mg/liter),
M220I (MIC, 0.5 mg/liter), and G54W (MIC,16 mg/liter) mutants. The
curve is the model fit with the Hill equation for pooled data.
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drug showed no meaningful efficacy in mice infected with the
G54W-containing isolate, which exhibited no in vitro suscepti-
bility to posaconazole.
Recently, Arendrup et al. (3) showed reduced efficacy of
posaconazole in a neutropenic murine model of invasive as-
pergillosis against a multiazole-resistant A. fumigatus isolate
(posaconazole MIC, 4 mg/liter), genetically identified as an
M220K mutant of the cyp51A gene. However, the study did not
investigate a full dose range of posaconazole. In our study,
treatment with posaconazole significantly prolonged survival at
a dose of 64 mg/kg for mice infected with the TR L98H or
M220I mutated isolate as well as for those infected with the
wild-type control isolate. Interestingly, although the TR L98H
and M220I isolates had the same MIC, efficacy comparable to
that for the mice infected with the wild-type isolate could be
achieved only with the TR L98H isolate at a higher posacon-
azole dose, and not at all with the M220I isolate. This suggests
that the underlying resistance mechanism may have an impact
on drug efficacy in addition to the phenotype, i.e., MIC. This
topic requires further investigation, since our study was not
sufficiently powered to determine significant differences be-
tween the TR L98H and M220I isolates. Also, other factors,
such as the presence of virulence factors or the fitness of the
different isolates, might be important. In this respect, our model
did not reveal significant differences in inoculum size and sur-
vival between wild-type isolates and those with Cyp51A muta-
tions, although additional studies of the impact of mutations
on the fitness of isolates are warranted.
A previous study with a murine model of candidiasis (1)
demonstrated that the pharmacokinetic behavior of posacon-
azole was nonlinear for single administrations of doses within
the range of 20 to 320 mg/kg. Our investigation revealed a
linear PK profile for multiple posaconazole administrations in
doses as high as 16 mg/kg. As with humans (7), the plasma drug
concentration for the 1- to 16-mg/kg dose range increased
proportionally to the dose. Nomeir and colleagues (24) studied
single administrations of posaconazole in the dose range of 20
to 160 mg/kg and reported that the dose-related increase in the
AUC was slower than that in Cmax, which was explained by
slower absorption at higher doses. We observed the same Cmax
effect within the dose-range of 1 to 64 mg/kg. In addition, there
was a 2-fold increase in oral clearance (CLss/F) at a dose of 64
mg/kg. This was an unexpected finding, since the limited me-
tabolism of posaconazole is mediated predominantly through
the UDP-glucuronosyltransferase (UGT) enzyme pathway
(11) and not through both the UGT and CYP (cytochrome
P450) pathways, as usually reported in the literature on the
metabolism of most hepatically cleared xenobiotics and
endobiotics. In humans, only 15% of the total posaconazole
dose is metabolized, and the majority of the metabolites are
glucuronide conjugates (14), excreted mostly in feces. There-
fore, it was more likely that for mice, oral clearance would
remain unchanged with an increase in dose. However, since no
data have been obtained after administration with full bioavail-
ability, it is not clear whether lower AUCs are due to increased
clearance or to lower absorption. These findings do indicate
that it is important to use AUCs based on measured pharma-
cokinetic profiles rather than the dose as a measure of drug
exposure.
Given that the pharmacokinetic profile of posaconazole in
both humans and mice is near-linear, an important question is
whether we could use the observations from our murine model
to predict if humans with azole-resistant aspergillosis can still
be treated with posaconazole, and which doses are needed to
result in efficacy. In our studies, maximum survival was achieved
for mice infected with the wild-type isolate, with a MIC of
0.031 mg/liter. This corresponded with an AUC/MIC ratio of
around 1,000 for total drug. This value is comparable to the
AUC/MIC ratios for Candida species found by Andes and
colleagues (1) and indicates that the pharmacokinetic/pharma-
codynamic relationships found for yeasts are comparable to
those for A. fumigatus. We did not determine the degree of
protein binding of posaconazole in our model, but at present
there are no indications that protein binding of posaconazole
in humans and mice differ to a great extent, and that for mice
is 98 to 99% (1). In fact, the dose-normalized AUC values are
similar in mice and humans, around 10 per mg/kg in both cases,
at least as determined with human volunteers (7). Thus, for
strains for which MICs are 0.5 mg/liter, a 50-mg/kg dose of
posaconazole would be needed for an optimal effect, or 4 g per
day for a human weighing 80 kg if the survival end point used
in this study is meaningful for predicting clinical outcome.
While this is not feasible at present, the AUC/MIC relation-
ship also indicates that some effect is reached at ratios of 100,
or 400 mg/day. The EI50 was 321, and this is reached with 1,200
mg per day. Thus, if no alternative treatment option is avail-
able, higher doses of posaconazole may in part overcome the
decreased susceptibility. The AUC/MIC relationship can also
be used to determine optimal doses for patients who have a
higher clearance or who display nonlinear exposure-dose rela-
tionships. For instance, Ullmann and colleagues (26) adminis-
tered posaconazole to bone marrow transplant (BMT) patients
and other patients with probable fungal infections, and the
total drug AUC0–24 levels were at least 4-fold less than those
for healthy volunteers (7), even though posaconazole doses
were higher than 800 mg. The AUCs obtained were, however,
sufficient to treat wild-type isolates.
With respect to the discussion above, two issues should be
noted. The first is that we used survival as an end point. While
this is the most stringent measure of drug efficacy, there are
some caveats, as discussed elsewhere (21, 30). The second is
that we used an intravenous model and therefore studied dis-
seminated aspergillosis, while most human infections are pul-
monary infections, in which dissemination, if present, is from
the lungs. It would be interesting to determine whether the
effects observed in a pulmonary model would corroborate
those found here with respect to the pharmacodynamic target.
We conclude that our model supports the view that the
efficacy of posaconazole treatment in A. fumigatus is depen-
dent both on drug exposure and on the MIC for the isolate, as
with other antifungal drugs (21, 30). In addition, the quantita-
tive relationship between exposure and effect is comparable to
that found for Candida strains (1). These relationships can be
used to optimize the treatment of human infections.
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